Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 177-183

  Hein, Sibyll ^a   Mahner, Sven ^a   Kanowski, Christine ^a   Löning, Thomas ^b   Jänicke, Fritz ^a   Milde Langosch, Karin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ALBERTINEN KRANKENHAUS   (Germany)

Author keywords

Activating protein 1; Borderline tumor; Expression; Fos; Jun; Metastasis; Ovarian cancer

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; PROTEIN C FOS; PROTEIN C JUN; PROTEIN FOS; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FOS-RELATED ANTIGEN-2; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; TIME FACTORS; TRANSCRIPTION FACTOR AP-1;

EID: 68249155405     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000422     Document Type: Article

References (27)

1. American-Cancer-Society Cancer Facts and Figures, 2007.
2. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and Pfisterer J: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329, 2003.
3. Deanne NG, Parker MA and Beauchamp RD: Cell proliferation: a matter of time and place. Surgery 138: 1-7, 2005.
4. Yamaguchi H, Wyckhoff J and Condeelis J: Cell migration in tumors. Curr Opin Cell Biol 17: 559-564, 2005.
5. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E and Tulchinsky E: Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18: 7095-7105, 1998.
6. Ozanne BW, Spence HJ, McGarry LC and Hennigan RF: Transcription factors control invasion: AP-1 the first among equals. Oncogene 26: 1-10, 2007.
7. Curran T and Franza BJ: Fos and Jun: the AP-1 connection. Cancer Res 55: 395-397, 1988.
8. Chinenov Y and Kerppola TK: Close encounters of man kinds: Fos-Jun interactions that mediate transcription regulatory specifity. Oncogene 20: 2438-2452, 2001.
9. Belguise K, Kersual N, Galtier F and Chalbos D: FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24: 1434-1444, 2005.
10. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH and Birrer MJ: cJun overexpression in MCF-7 breast cancer cells produces tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063-6070, 1999.
11. Soto U, Denk C, Finzer P, Hutter K-J, Hausen H and Rösl F: Genetic complementation to non-tumorigenecity in cervicalcarcinoma cells correlates with alterations in AP-1 composition. Int J Cancer 86: 811-817, 2000.
12. Milde-Langosch K, Röder H, Andritzky B, Aslan B, Hemminger G, Brinkmann G, Bamberger CM, Löning T and Bamberger AM: The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 86: 139-152, 2004.
13. Zajchowski D, Bartholdi M, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP and Johnson PH: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61: 5168-5178, 2001.
14. Milde-Langosch K: The Fos family of transcription factors and their role in tumorigenesis. Eur J Cancer 41: 2449-2461, 2005.
15. Tkach V, Tulchinsky E, Lukanidin E, Vinson C, Bock E and Berezin V: Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in regulation of cell motility. Oncogene 22: 5045-5054, 2003.
16. Milde-Langosch K, Bamberger A-M, Goemann C, Rössing E, Rieck G, Kelp B and Löning T: Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 127: 537-544, 2001.
17. Misra A, Lim RPZ, Wu Z and Thanabalu T: N-WASP plays a critical role in fibroblast adhesion and spreading. Biochem Biophys Res Commun 364: 908-912, 2007.
18. Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T and Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of FosB expression with a well-differentiated, receptor-positiv tumor phenotype. Int J Cancer 84: 533-538, 1999.
19. Jochum W, Passegué E and Wagner EF: AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401-2412, 201.
20. Ozanne BW, McGarry LC, Spence HJ, Johnston I, Winnie J, Meagher L and Stapleton G: Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 36: 1640-1648, 2000.
21. Ryseck R-P and Bravo R: c-Jun, JunB, and JunD differ in their binding affinities to AP-1 and CRE consensus sequences: effect of fos proteins. Oncogene 6: 533-542, 1991.
22. Milde-Langosch K, Janke S, Wagner I, Schröder C, Streichert T, Bamberger A-M, Jänicke F and Löning T: Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Cancer Res Treat 107: 337-347, 2008.
23. Tchernitsa OI, Sers C, Zuber J, Hinzmann B, Grips M, Schramme A, Lund P, Schwendel A, Rosenthal A and Schäfer R: Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene 23: 4536-4555, 2004.
24. Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Hofler H, Schmitt M and Reuning U: Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/vitronectin interaction. Biol Chem 384: 1073-1083, 2003.
25. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttgers J, Krajewski M, Krajewski S, Reed JC, Arnold N and Hampton GM: Molecular and prognostic distinction between serous carcinomas of varying and malignant potential. Oncogene 24: 1053-1065, 2004.
26. Gilks CB, Vanderhyden BC, Zhu S, van Rijn M and de Longarcre TA: Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96: 684-694, 2005.
27. Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F and Milde-Langosch K: C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99: 1269-1275, 2008.